Downregulation of plasma miR-215 in chronic myeloid leukemia patients with successful discontinuation of imatinib

International Journal of Molecular Sciences

Volumn 17, Issue 4, 2016, Pages

  Ohyashiki, Kazuma ^a   Umezu, Tomohiro ^a   Katagiri, Seiichiro ^a   Kobayashi, Chiaki ^a   Azuma, Kenko ^a   Tauchi, Tetsuzo ^a   Okabe, Seiichi ^a   Fukuoka, Yutaka ^b   Ohyashiki, Junko H ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

^b KOGAKUIN UNIVERSITY   (Japan)

Author keywords

Chronic myeloid leukemia; Discontinuation; Imatinib; Plasma miR 215

Indexed keywords

IMATINIB; MICRORNA; MICRORNA 215; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; MIRN215 MICRORNA, HUMAN;

ADULT; ARTICLE; BIOINFORMATICS; CELL CYCLE CHECKPOINT; CELLULAR STRESS RESPONSE; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DNA REPAIR; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; MIDDLE AGED; MINIMAL RESIDUAL DISEASE; MOLECULAR GENETICS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RECEIVER OPERATING CHARACTERISTIC; RECEPTOR DOWN REGULATION; SEQUENCE ANALYSIS; WESTERN BLOTTING; BLOOD; DOWN REGULATION; DRUG EFFECTS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE;

ANTINEOPLASTIC AGENTS; DOWN-REGULATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMATINIB MESYLATE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MICRORNAS;

EID: 84963730001     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms17040570     Document Type: Article

References (37)

1. Hochhaus, A.; O’Brien, S.G.; Guilhot, F.; Druker, B.J.; Branford, S.; Foroni, L.; Goldman, J.M.; Müller, M.C.; Radich, J.P.; Rudoltz, M.; et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 2009, 23, 1054–1061. [CrossRef] [PubMed]
2. Baccarani, M.; Deininger, M.W.; Rosti, G.; Hochhaus, A.; Soverini, S.; Apperley, J.F.; Cervantes, F.; Clark, R.E.; Cortes, J.E.; Guilhot, F.; et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 2013, 122, 872–884. [CrossRef] [PubMed]
3. Mahon, F.X.; Réa, D.; Guilhot, J.; Guilhot, F.; Huguet, F.; Nicolini, F.; Legros, L.; Charbonnier, A.; Guerci, A.; Varet, B.; et al. Intergroupe Français des Leucémies Myéloïdes Chroniques. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: The prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010, 11, 1029–1035.[CrossRef]
4. Ross, D.M.; Branford, S.; Seymour, J.F.; Schwarer, A.P.; Arthur, C.; Yeung, D.T.; Dang, P.; Goyne, J.M.; Slader, C.; Filshie, R.J.; et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: Results from the TWISTER study. Blood 2013, 122, 515–522. [CrossRef] [PubMed]
5. Branford, S.; Yeung, D.T.; Parker, W.T.; Roberts, N.D.; Purins, L.; Braley, J.A.; Altamura, H.K.; Yeoman, A.L.; Georgievski, J.; Jamison, B.A.; et al. Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline. Blood 2014, 124, 511–518. [CrossRef] [PubMed]
6. Yoshimoto, T.; Mizoguchi, I.; Katagiri, S.; Tauchi, T.; Furusawa, J.I.; Chiba, Y.; Mizuguchi, J.; Ohyashiki, J.H.; Ohyashiki, K. Immunosurveillance markers may predict patients who can discontinue imatinib therapy without relapse. Oncoimmunology 2014, 3, e28861. [CrossRef] [PubMed]
7. Tanaka, M.; Oikawa, K.; Takanashi, M.; Kudo, M.; Ohyashiki, J.; Ohyashiki, K.; Kuroda, M. Down-regulation of miR-92 in human plasma is a novel marker for acute leukemia patients. PLoS ONE 2009, 4, e5532. [CrossRef] [PubMed]
8. Ohyashiki, K.; Umezu, T.; Yoshizawa, S.; Ito, Y.; Ohyashiki, M.; Kawashima, H.; Tanaka, M.; Kuroda, M.; Ohyashiki, J.H. Clinical impact of down-regulated plasma miR-92a levels in non-Hodgkin’s lymphoma. PLoS ONE 2011, 6, e16408. [CrossRef] [PubMed]
9. Yoshizawa, S.; Ohyashiki, J.H.; Ohyashiki, M.; Umezu, T.; Suzuki, K.; Inagaki, A.; Iida, S.; Ohyashiki, K. Downregulated plasma miR-92a levels have clinical impact on multiple myeloma and related disorders. Blood Cancer J. 2012, 2, e53. [CrossRef] [PubMed]
10. Tadokoro, H.; Umezu, T.; Ohyashiki, K.; Hirano, T.; Ohyashiki, J.H. Exosomes derived from hypoxic leukemia cells enhance tube formation in endothelial cells. J. Biol. Chem. 2013, 288, 34343–34351. [CrossRef] [PubMed]
11. Umezu, T.; Tadokoro, H.; Azuma, K.; Yoshizawa, S.; Ohyashiki, K.; Ohyashiki, J.H. Exosomal miR-135b shed from hypoxic multiple myeloma cells enhances angiogenesis by targeting factor-inhibiting HIF-1. Blood 2014, 124, 3748–3757. [CrossRef] [PubMed]
12. Kosaka, N.; Iguchi, H.; Ochiya, T. Circulating microRNA in body fluid: A new potential biomarker for cancer diagnosis and prognosis. Cancer Sci. 2010, 101, 2087–2092. [CrossRef] [PubMed]
13. Ohyashiki, J.H.; Ohtsuki, K.; Mizoguchi, I.; Yoshimoto, T.; Katagiri, S.; Umezu, T.; Ohyashiki, K. Downregulated microRNA-148b in circulating PBMCs in chronic myeloid leukemia patients with undetectable minimal residual disease: A possible biomarker to discontinue imatinib safely. Drug Des. Dev. Ther. 2014, 8, 1151–1159. [CrossRef] [PubMed]
14. Elvira-Matelot, E.; Zhou, X.O.; Farman, N.; Beaurain, G.; Henrion-Caude, A.; Hadchouel, J.; Jeunemaitre, X. Regulation of WNK1 expression by miR-192 and aldosterone. J. Am. Soc. Nephrol. 2010, 21, 1724–1731. [CrossRef] [PubMed]
15. Georges, S.A.; Biery, M.C.; Kim, S.Y.; Schelter, J.M.; Guo, J.; Chang, A.N.; Jackson, A.L.; Carleton, M.O.; Linsley, P.S.; Cleary, M.A.; et al. Coordinated regulation of cell cycle transcripts by p53-Inducible microRNAs, miR-192 and miR-215. Cancer Res. 2008, 68, 10105–10112. [CrossRef] [PubMed]
16. Jin, Z.; Selaru, F.M.; Cheng, Y.; Kan, T.; Agarwal, R.; Mori, Y.; Olaru, A.V.; Yang, J.; David, S.; Hamilton, J.P.; et al. MicroRNA-192 and -215 are upregulated in human gastric cancer in vivo and suppress ALCAM expression in vitro. Oncogene 2011, 30, 1577–1585. [CrossRef] [PubMed]
17. White, N.M.; Khella, H.W.; Grigull, J.; Adzovic, S.; Youssef, Y.M.; Honey, R.J.; Stewart, R.; Pace, K.T.; Bjarnason, G.A.; Jewett, M.A.; et al. miRNA profiling in metastatic renal cell carcinoma reveals a tumour-suppressor effect for miR-215. Br. J. Cancer 2011, 105, 1741–1749. [CrossRef] [PubMed]
18. Liu, F.; You, X.; Chi, X.; Wang, T.; Ye, L.; Niu, J.; Zhang, X. Hepatitis B virus X protein mutant HBxD127 promotes proliferation of hepatoma cells through up-regulating miR-215 targeting PTPRT. Biochem. Biophys. Res. Commun. 2014, 444, 128–134. [CrossRef] [PubMed]
19. Senanayake, U.; Das, S.; Vesely, P.; Alzoughb, W.F.; Fröhlich, L.; Chowdhury, P.; Leuschner, I.; Hoefler, G.; Guertl, B. miR-192, miR-194, miR-215, miR-200c and miR-141 are downregulated and their common target ACVR2B is strongly expressed in renal childhood neoplasms. Carcinogenesis 2012, 33, 1014–1021. [CrossRef] [PubMed]
20. Mu, J.; Pang, Q.; Guo, Y.H.; Chen, J.G.; Zeng, W.; Huang, Y.J.; Zhang, J.; Feng, B. Functional implications of microRNA-215 in TGF-1-induced phenotypic transition of mesangial cells by targeting CTNNBIP1. PLoS ONE 2013, 8, e58622. [CrossRef] [PubMed]
21. Song, B.; Wang, Y.; Titmus, M.A.; Botchkina, G.; Formentini, A.; Kornmann, M.; Ju, J. Molecular mechanism of chemoresistance by miR-215 in osteosarcoma and colon cancer cells. Mol. Cancer 2010, 30, 96. [CrossRef] [PubMed]
22. Lipchina, I.; Elkabetz, Y.; Hafner, M.; Sheridan, R.; Mihailovic, A.; Tuschl, T.; Sander, C.; Studer, L.; Betel, D. Genome-wide identification of microRNA targets in human ES cells reveals a role for miR-302 in modulating BMP response. Genes Dev. 2011, 25, 2173–2186. [CrossRef] [PubMed]
23. Skalsky, R.L.; Corcoran, D.L.; Gottwein, E.; Frank, C.L.; Kang, D.; Hafne, M.; Nusbaum, J.D.; Feederle, R.; Delecluse, H.J.; Luftig, M.A.; et al. The viral and cellular microRNA targetome in lymphoblastoid cell lines. PLoS Pathog. 2012, 8, e1002484. [CrossRef] [PubMed]
24. The Database for Annotation, Visualization and Integrated Discovery (DAVIS Bioinformatics Tools v6.7). Available online: http://david.abcc.ncifcrf.gov (accessed on 13 April 2016).
25. Grasedieck, S.; Sorrentino, A.; Langer, C.; Buske, C.; Dohner, H.; Mertens, D.; Kuchenbauer, F. Circulating microRNAs in hematological diseases: Principles, challenges, and perspectives. Blood 2013, 121, 4977–4984. [CrossRef] [PubMed]
26. Pichiorri, F.; Suh, S.S.; Rocci, A.; de Luca, L.; Taccioli, C.; Santhanam, R.; Zhou, W.; Benson, D.M.J.; Hofmainster, C.; Alder, H.; et al. Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development. Cancer Cell 2010, 18, 367–381. [CrossRef] [PubMed]
27. Chiang, Y.; Zhou, X.; Wang, Z.; Song, Y.; Liu, Z.; Zhao, F.; Zhu, J.; Xu, H. Expression levels of microRNA-192 and -215 in gastric carcinoma. Pathol. Oncol. Res. 2012, 18, 585–591. [CrossRef] [PubMed]
28. Gu, L.; Li, H.; Chen, L.; Ma, X.; Gao, Y.; Li, X.; Zhang, Y.; Fan, Y.; Zhang, X. Micro RNAs as prognostic molecular signatures in renal cell carcinoma: A systematic review and meta-analysis. Oncotarget 2015, 6, 32545–32560. [PubMed]
29. Tong, Y.Q.; Liu, B.; Zheng, H.Y.; Gu, J.; Liu, F.; Tan, B.H.; Hartman, M.; Song, C.; Li, Y. MIR-215, an activator of the CTNNBIP1/-catenin pathway, is a marker of poor prognosis in human glioma. Oncotarget 2015, 6, 25024–25033. [CrossRef] [PubMed]
30. Choi, D.H.; Park, S.J.; Kim, H.K. Mir-215 overexpression distinguishes ampullary carcinomas from pancreatic carcinomas. Hepatobiliary Pancreat. Dis. Int. 2015, 14, 325–329. [CrossRef]
31. Slattery, M.L.; Ferrick, J.S.; Mullany, L.E.; Valeri, N.; Stevens, J.; Caan, B.J.; Samowitz, W.; Wolff, R.K. An evaluation and replication of miRNAs with disease stage and colorectal cancer-specific mortality. Int. J. Cancer 2015, 137, 428–438. [CrossRef] [PubMed]
32. Deng, Y.; Huang, Z.; Xu, Y.; Jin, J.; Zhuo, W.; Zhang, C.; Zhang, X.; Shen, M.; Yan, X.; Wang, L.; et al. miR-215 modulates gastric cancer cell proliferation by targeting RB1. Cancer Lett. 2014, 342, 27–35. [CrossRef] [PubMed]
33. Hsu, S.D.; Lin, F.M.; Wu, W.Y.; Liang, C.; Huang, W.C.; Chan, W.L.; Tsai, W.T.; Chen, G.Z.; Lee, C.J.; Chiu, C.M.; et al. miRTarBase: A database curates experimentally validated microRNA-target interactions. Nucleic Acids Res. 2011, 39, gkq107. [CrossRef] [PubMed]
34. Braun, C.J.; Zhang, X.; Savelyeva, I.; Wolff, S.; Moll, U.M.; Schepeler, T.; Ørntoft, T.F.; Andersen, C.L.; Dobbelstein, M. p53-Responsive micrornas 192 and 215 are capable of inducing cellcycle arrest. Cancer Res. 2008, 68, 10094–10104. [CrossRef] [PubMed]
35. Skottman, H.; Mikkola, M.; Lundin, K.; Olsson, C.; Strömberg, A.M.; Tuuri, T.; Otonkoski, T.; Hovatta, O.; Lahesmaa, R. Gene expression signatures of seven individual human embryonic stem cell lines. Stem Cells 2005, 23, 1343–1356. [CrossRef] [PubMed]
36. Pera, M.F.; Tam, P.P. Extrinsic regulation of pluripotent stem cells. Nature 2010, 465, 713–720. [CrossRef] [PubMed]
37. The experimentally-validated miRNA-target interactions database (miRTarBase). Available online: http://mirtarbase.mbc.nctu.edu.tw/ (accessed on 13 April 2016).